Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.

Aged Cytostatic Agents / administration & dosage Feasibility Studies Female Follow-Up Studies Humans Leukocyte Count Male Middle Aged Platelet Count / standards Prognosis Reference Values Retrospective Studies Risk Factors Thrombocythemia, Essential / blood Thrombosis / blood World Health Organization

Diagnostic threshold Platelets Real-life assessment Thrombosis WHO classification

Journal

Clinical lymphoma, myeloma & leukemia

ISSN: 2152-2669

Titre abrégé: Clin Lymphoma Myeloma Leuk

Pays: United States

ID NLM: 101525386

Informations de publication

Date de publication:
04 2021

Historique:

received: 27 09 2020

revised: 31 10 2020

accepted: 02 11 2020

pubmed: 22 12 2020

medline: 11 1 2022

entrez: 21 12 2020

Statut: ppublish

Résumé

According to 2008/2016 classification of the World Health Organization (WHO), a platelet (PLT) count ≥ 450 × 10 To validate this important diagnostic change in a setting of current clinical practice, we retrospectively analyzed clinical and hematologic features at diagnosis and during follow-up of 162 patients with ET, diagnosed in our center from January 2008 to December 2017. We subdivided patients according to PLT value at baseline into Group A (PLT ≥ 600 × 10 Among clinical features, only the median value of leukocytes (P < .001) was significantly higher in Group A. Cytostatic treatment was administered in 103 patients, with a significantly higher rate in patients of group A (P < .001). After a median follow-up of 42.4 months (interquartile range, 22.1-70.6 months), 8 thrombotic events were recorded in the entire cohort, without differences between the 2 groups (P = .336). The 5-year overall survival (OS) of the entire cohort was 96.9% (95% confidence interval, 92.6%-100%), without differences between the 2 groups (P = .255). Our data indicate a substantial homogeneity among patients with ET regardless of the PLT count at diagnosis, thus confirming the usefulness of the 2008/2016 WHO diagnostic criteria.

Sections du résumé

BACKGROUND

According to 2008/2016 classification of the World Health Organization (WHO), a platelet (PLT) count ≥ 450 × 10

PATIENTS AND METHODS

To validate this important diagnostic change in a setting of current clinical practice, we retrospectively analyzed clinical and hematologic features at diagnosis and during follow-up of 162 patients with ET, diagnosed in our center from January 2008 to December 2017. We subdivided patients according to PLT value at baseline into Group A (PLT ≥ 600 × 10

RESULTS

Among clinical features, only the median value of leukocytes (P < .001) was significantly higher in Group A. Cytostatic treatment was administered in 103 patients, with a significantly higher rate in patients of group A (P < .001). After a median follow-up of 42.4 months (interquartile range, 22.1-70.6 months), 8 thrombotic events were recorded in the entire cohort, without differences between the 2 groups (P = .336). The 5-year overall survival (OS) of the entire cohort was 96.9% (95% confidence interval, 92.6%-100%), without differences between the 2 groups (P = .255).

CONCLUSIONS

Our data indicate a substantial homogeneity among patients with ET regardless of the PLT count at diagnosis, thus confirming the usefulness of the 2008/2016 WHO diagnostic criteria.

Identifiants

DOI: 10.1016/j.clml.2020.11.003 PMID: 33342728

pubmed: 33342728

pii: S2152-2650(20)30616-9

doi: 10.1016/j.clml.2020.11.003

pii:

doi:

Substances chimiques

Cytostatic Agents 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

e328-e333